Martin Kleinschmidt1,2, Robby Schoenfeld3, Claudia Göttlich1,4, Daniel Bittner5, Jürgen Erich Metzner6, Bernd Leplow3, Hans-Ulrich Demuth1,2. 1. Probiodrug AG, Halle (Saale), Germany. 2. Current address: Fraunhofer Institute of Cell Therapy and Immunology, Department of Drug Design and Target Validation, Halle (Saale), Germany. 3. Martin-Luther-University Halle-Wittenberg, Department of Psychology, Halle (Saale), Germany. 4. Department Tissue Engineering & Regenerative Medicine (TERM), University Hospital Wuerzburg, Germany. 5. Clinic for Neurology, Otto-von-Guericke University Magdeburg, Germany. 6. Galmed GmbH, Halle (Saale), Germany.
Abstract
BACKGROUND: Current treatment in Alzheimer's disease (AD) is initiated at a stage where the brain already has irreversible structural deteriorations. Therefore, the concept of treatment prior to obvious cognitive deficits has become widely accepted, and simple biochemical tests to discriminate normal aging from prodromal or demented stages are now common practice. OBJECTIVE: The objective of the study was the differentiation of controls, mild cognitive impairment (MCI) and AD patients by novel blood-based assays in combination with neuropsychological tests. METHODS: In a cross-sectional study, 143 subjects aged 18 to 85 years were recruited. All participants were classified by a comprehensive neuropsychological assessment. Blood samples were analyzed for several amyloid-β (Aβ) species, pro-inflammatory markers, anti-Aβ autoantibodies, and ApoE allele status, respectively. RESULTS: Plasma Aβ1-42 was significantly decreased in MCI and AD compared to age-matched controls, whereas Aβ1-40 did not differ, but increases with age in healthy controls. The Aβ1-42 to Aβ1-40 ratio was stepwise decreased from age-matched controls via MCI to AD, and shows a clear correlation with memory scores. Reduced Aβ1-42 and Aβ1-42 to Aβ1-40 ratio have strongly correlated with carrying ApoE ɛ4 allele. Autoantibodies against pyroglutamate-modified Aβ, but only a certain subclass, were significantly decreased in AD compared to MCI and age-matched controls, whereas autoantibodies against the unmodified N-terminus of Aβ did not differ. CONCLUSION: Comprehensive sample preparation and assay standardization enable reliable usage of plasma Aβ for diagnosis of MCI and AD. Anti-pGlu-Aβ autoantibodies correlate with cognition, but not with ApoE, supporting the associated plasma Aβ analysis with additional and independent information.
BACKGROUND: Current treatment in Alzheimer's disease (AD) is initiated at a stage where the brain already has irreversible structural deteriorations. Therefore, the concept of treatment prior to obvious cognitive deficits has become widely accepted, and simple biochemical tests to discriminate normal aging from prodromal or demented stages are now common practice. OBJECTIVE: The objective of the study was the differentiation of controls, mild cognitive impairment (MCI) and ADpatients by novel blood-based assays in combination with neuropsychological tests. METHODS: In a cross-sectional study, 143 subjects aged 18 to 85 years were recruited. All participants were classified by a comprehensive neuropsychological assessment. Blood samples were analyzed for several amyloid-β (Aβ) species, pro-inflammatory markers, anti-Aβ autoantibodies, and ApoE allele status, respectively. RESULTS: Plasma Aβ1-42 was significantly decreased in MCI and AD compared to age-matched controls, whereas Aβ1-40 did not differ, but increases with age in healthy controls. The Aβ1-42 to Aβ1-40 ratio was stepwise decreased from age-matched controls via MCI to AD, and shows a clear correlation with memory scores. Reduced Aβ1-42 and Aβ1-42 to Aβ1-40 ratio have strongly correlated with carrying ApoE ɛ4 allele. Autoantibodies against pyroglutamate-modified Aβ, but only a certain subclass, were significantly decreased in AD compared to MCI and age-matched controls, whereas autoantibodies against the unmodified N-terminus of Aβ did not differ. CONCLUSION: Comprehensive sample preparation and assay standardization enable reliable usage of plasma Aβ for diagnosis of MCI and AD. Anti-pGlu-Aβ autoantibodies correlate with cognition, but not with ApoE, supporting the associated plasma Aβ analysis with additional and independent information.
Authors: Marat A Mukhamedyarov; Albert A Rizvanov; Eduard Z Yakupov; Andrey L Zefirov; Andrey P Kiyasov; Helton J Reis; Antônio L Teixeira; Luciene B Vieira; Luciana M Lima; Ilnur I Salafutdinov; Elena O Petukhova; Svetlana F Khaiboullina; Karen A Schlauch; Vincent C Lombardi; András Palotás Journal: J Alzheimers Dis Date: 2016-10-18 Impact factor: 4.472
Authors: Lih-Fen Lue; Marwan N Sabbagh; Ming-Jang Chiu; Naomi Jing; Noelle L Snyder; Christopher Schmitz; Andre Guerra; Christine M Belden; Ta-Fu Chen; Che-Chuan Yang; Shieh-Yueh Yang; Douglas G Walker; Kewei Chen; Eric M Reiman Journal: Front Aging Neurosci Date: 2017-07-24 Impact factor: 5.750
Authors: Claire Bridel; Torsten Hoffmann; Antje Meyer; Sisi Durieux; Marleen A Koel-Simmelink; Matthias Orth; Philip Scheltens; Inge Lues; Charlotte E Teunissen Journal: Alzheimers Res Ther Date: 2017-06-06 Impact factor: 6.982
Authors: Matthew J Yousefzadeh; Marissa J Schafer; Nicole Noren Hooten; Elizabeth J Atkinson; Michele K Evans; Darren J Baker; Ellen K Quarles; Paul D Robbins; Warren C Ladiges; Nathan K LeBrasseur; Laura J Niedernhofer Journal: Aging Cell Date: 2017-12-31 Impact factor: 9.304
Authors: Hedieh Shahpasand-Kroner; Hans-W Klafki; Chris Bauer; Johannes Schuchhardt; Melanie Hüttenrauch; Martina Stazi; Caroline Bouter; Oliver Wirths; Jonathan Vogelgsang; Jens Wiltfang Journal: Alzheimers Res Ther Date: 2018-12-08 Impact factor: 6.982